Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
{{output}}
Objective: Vesicular monoamine transporter-2 (VMAT2) inhibitors have been proven to be effective for the treatment of tardive dyskinesia and their use is likely to increase. The evidence base of published clinical reports was rev... ...